Skip to content
value.today
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc.

AMRX
$6.7 Bmarket cap on Oct 16, 2026+270.8% since Jan 2024
1M
+6.5%
Compare
World rank
#2,900
Revenue
$3.0 B
For year ending December-2025
Net income
$72 M
2.4% margin
SEC filing
Employees
8,500
As of December 31, 2025
SEC filing

Amneal Pharmaceuticals, Inc. in brief

Amneal Pharmaceuticals, Inc. is a listed company in the Pharmaceutical industry, based in New Jersey, USA. Its market value was $6.7 B on 16 October 2026, which makes it the 2,900th largest listed company in the world and the 885th largest in the USA on this site. In the year to December 2025 it had sales of $3.0 B and a net profit of $72 M, about 2 cents of profit for every dollar of sales. It employs about 8,500 people and Chintu Patel is its chief executive. Its largest product and service lines by sales in 2025 were Subtotal dosage forms (57%), Oral solid (24%) and Subtotal therapeutic classes (17%). Its shares trade under the symbol AMRX (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Amneal Pharmaceuticals, Inc. timeline

8 events, 2017–2025
  1. 2017
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2018
  4. 🔔
    · approximate
    Initial public offering on NYSE
  5. •
    Legal Entity Identifier issued
    LEI 549300VV176ZO5WQHZ61 registered.
  6. ✎
    Renamed Amneal Pharmaceuticals, Inc.
    Formerly Atlas Holdings, Inc..
  7. 📉
    · approximate
    Delisted from Nasdaq
  8. 📈
    · approximate
    Listed on New York Stock Exchange as AMRX
  9. 2025
  10. 💰
    Record revenue of $3.0 billion
    FY2025, the highest of the 8 years on record.
  11. 💰
    Record net income of $72 million
    FY2025, the highest profit of the 3 years on record.

Events of Amneal Pharmaceuticals, Inc. from SEC EDGAR, the company record, the GLEIF LEI register, Wikidata and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$1.8 B$3.6 B$5.4 B$7.2 B2020202120222023202420252026

World rank over time

▲ up 3,066 places since 2020
2020-01-01: #5973#5,97320202021-01-01: #9724#9,72420212022-01-07: #11500#11,50020222022-12-25: #15083#15,08320222023-07-30: #8909#8,90920232024-01-05: #6044#6,04420242026-08-01: #3072#3,07220262026-09-17: #3047#3,04720262026-10-16: #2907#2,9072026

Rank in USA: #1,739 (Jan 2020) · #2,509 (Jan 2021) · #2,905 (Jan 2022) · #3,097 (Dec 2022) · #2,143 (Jul 2023) · #1,615 (Jan 2024) · #959 (Aug 2026) · #910 (Sep 2026) · #886 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
50.3×
Price / sales (TTM)
2.1×
Price / book
—
Free cash flow yield
4.0%
Net margin (TTM)
4.2%
Operating margin
13.1%
Return on equity
—
Liabilities / assets
101.9%
Net debt
$2.3B
Revenue growth
+8.0%
R&D / revenue
6.2%
Revenue per employee
$355 K
Profit per employee
$8 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1.7B, net income $-20M$1.7BFY18Fiscal year ending Dec 2019: revenue $1.6B, net income $-604M$1.6BFY19Fiscal year ending Dec 2020: revenue $2.0B, net income $68M$2.0BFY20Fiscal year ending Dec 2021: revenue $2.1B, net income $13M$2.1BFY21Fiscal year ending Dec 2022: revenue $2.2B, net income $-271M$2.2BFY22Fiscal year ending Dec 2023: revenue $2.4B, net income $-84M$2.4BFY23Fiscal year ending Dec 2024: revenue $2.8B, net income $-117M$2.8BFY24Fiscal year ending Dec 2025: revenue $3.0B, net income $72M$3.0BFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$3.0B+8.0%$394M$72M2.4%
Dec 2024$2.8B+16.7%$249M$-117M-4.2%
Dec 2023$2.4B+8.2%$204M$-84M-3.5%
Dec 2022$2.2B+5.7%$-95M$-271M-12.2%
Dec 2021$2.1B+5.1%$153M$13M0.6%
Dec 2020$2.0B+22.5%$91M$68M3.4%
Dec 2019$1.6B-2.2%$-249M$-604M-37.1%
Dec 2018$1.7B—$-20M$-20M-1.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$340M$70M$270M$0.22—
Dec 2024$295M$52M$243M$-0.38—
Dec 2023$346M$43M$302M$-0.48—
Dec 2022$65M$46M$19M$-0.86—
Dec 2021$242M$48M$194M$0.07—
Dec 2020$379M$56M$323M$0.61—
Dec 2019$2M$47M$-45M$-2.74—
Dec 2018$250M$83M$167M$-0.16—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$3.2B
Net income, trailing 12 months
$133M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $731M, net income $-31M$731MDec ’24Three months to Mar 2025: revenue $695M, net income $12M$695MMar ’25Three months to Jun 2025: revenue $725M, net income $22M$725MJun ’25Three months to Sep 2025: revenue $785M, net income $2M$785MSep ’25Three months to Dec 2025 (from the annual report): revenue $814M, net income $35M$814MDec ’25Three months to Mar 2026: revenue $723M, net income $62M$723MMar ’26Three months to Jun 2026: revenue $796M, net income $58M$796MJun ’26Three months to Sep 2026: revenue $863M, net income $-22M$863MSep ’26

Latest quarter to Sep 2026: revenue $863M (+10.0% on a year earlier), net income $-22M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

Annual and quarterly reports

Premium · account

Amneal Pharmaceuticals, Inc.'s reports from the last 8 years, from the official filing system. Downloads (Excel financial statements, PDF, the report as filed, or everything as a ZIP) are for Premium subscribers — sign in.

Annual · 8

Quarterly · 23

SEC filings

Official filings of Amneal Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$3.0 B
Operating income
$394 M
Net income
$72 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$3.7 B
Total liabilities
$3.7 B
Total equity
$-71 M

As of December-2025

Top 100 institutional investors in Amneal Pharmaceuticals, Inc.#

As of Sep 30, 2026
334 institutions held 169.2 M shares (about 48.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 28.4%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Amneal Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.26,877,188+315,095 (+1.19%)7.71%$541 MNov 13, 2026
2Vanguard Portfolio Management LLC12,365,663+227,936 (+1.88%)3.55%$249 MNov 13, 2026
3TPG GP A, LLC12,328,7670 (0.00%)3.54%$248 MNov 16, 2026
4Rubric Capital Management LP8,536,755-1,631,905 (-16.05%)2.45%$172 MNov 16, 2026
5Vanguard Capital Management LLC7,987,664+277,538 (+3.60%)2.29%$161 MNov 13, 2026
6State Street Corp7,471,033+114,056 (+1.55%)2.14%$150 MNov 12, 2026
7Citadel Advisors LLC6,993,701+5,874,986 (+525.15%)2.01%$141 MNov 16, 2026
8Invesco Ltd.5,965,042+2,463,042 (+70.33%)1.71%$120 MNov 12, 2026
9Dimensional Fund Advisors LP5,816,123+21,860 (+0.38%)1.67%$117 MNov 4, 2026
10Geode Capital Management, LLC4,568,902-570,547 (-11.10%)1.31%$92 MNov 6, 2026
11Morgan Stanley4,270,159+160,131 (+3.90%)1.23%$86 MNov 13, 2026
12Allspring Global Investments Holdings, LLC3,831,581+536,048 (+16.27%)1.10%$77 MNov 4, 2026
13Neuberger Berman Group LLC3,350,096-537,083 (-13.82%)0.96%$67 MNov 13, 2026
14Nuveen, LLC3,198,986-125,889 (-3.79%)0.92%$64 MNov 10, 2026
15Goldman Sachs Group Inc2,595,553-418,408 (-13.88%)0.74%$52 MNov 16, 2026
16Charles Schwab Investment Management Inc2,478,891+331,441 (+15.43%)0.71%$50 MNov 16, 2026
17Tri Locum Partners LP2,326,733New0.67%$47 MNov 16, 2026
18Nantahala Capital Management, LLC2,115,749-2,421,753 (-53.37%)0.61%$43 MNov 13, 2026
19Assenagon Asset Management S.A.2,026,781-2,864,317 (-58.56%)0.58%$41 MOct 15, 2026
20Northern Trust Corp1,823,873-91,022 (-4.75%)0.52%$37 MNov 16, 2026
21Ameriprise Financial Inc1,552,969-28,900 (-1.83%)0.45%$31 MNov 16, 2026
22Congress Asset Management Co1,524,355+741,577 (+94.74%)0.44%$31 MOct 6, 2026
23Balyasny Asset Management L.P.1,343,165+909,033 (+209.39%)0.39%$27 MNov 16, 2026
24Acadian Asset Management LLC1,296,266-353,989 (-21.45%)0.37%$26 MNov 9, 2026
25Vanguard Fiduciary Trust Co1,228,472+59,190 (+5.06%)0.35%$25 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Amneal Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26FMR LLC1,209,248+384,128 (+46.55%)0.35%$24 MNov 10, 2026
27Principal Financial Group Inc1,146,813+154,996 (+15.63%)0.33%$23 MNov 2, 2026
28Public Sector Pension Investment Board1,026,235+434,400 (+73.40%)0.29%$21 MNov 10, 2026
29Bank of New York Mellon Corp996,932-18,250 (-1.80%)0.29%$20 MNov 5, 2026
30First Trust Advisors LP955,599+341,393 (+55.58%)0.27%$19 MNov 12, 2026
31UBS Group AG902,453+458,053 (+103.07%)0.26%$18 MNov 10, 2026
32Raymond James Financial Inc874,367+97,099 (+12.49%)0.25%$18 MNov 12, 2026
33PFM Health Sciences, LP822,891+342,176 (+71.18%)0.24%$17 MNov 16, 2026
34Panagora Asset Management Inc790,578+346,931 (+78.20%)0.23%$16 MNov 12, 2026
35Bank Of America Corp /de/779,565-15,972 (-2.01%)0.22%$16 MNov 16, 2026
36BNP Paribas Financial Markets727,677+62,787 (+9.44%)0.21%$15 MNov 12, 2026
37Soleus Capital Management, L.P.658,000New0.19%$13 MNov 16, 2026
38Pictet Asset Management Holding SA638,040+26,810 (+4.39%)0.18%$13 MNov 3, 2026
39SEI Investments Co636,995-53,902 (-7.80%)0.18%$13 MNov 10, 2026
40AQR Capital Management LLC623,998-171,030 (-21.51%)0.18%$13 MNov 16, 2026
41Prudential Financial Inc620,428+289,260 (+87.35%)0.18%$12 MNov 16, 2026
42Jpmorgan Chase & Co617,276-177,724 (-22.36%)0.18%$12 MNov 12, 2026
43D. E. Shaw & Co., Inc.568,653-205,402 (-26.54%)0.16%$11 MNov 16, 2026
44Tucker Asset Management LLC511,064-500,000 (-49.45%)0.15%$10 MOct 29, 2026
45Woodline Partners LP482,264New0.14%$10 MNov 16, 2026
46Voleon Capital Management LP464,452-21,600 (-4.44%)0.13%$9 MNov 16, 2026
47Amundi440,347+400,457 (+1003.90%)0.13%$9 MNov 6, 2026
48Quartz Partners, LLC433,074-23,017 (-5.05%)0.12%$9 MNov 3, 2026
49Exchange Traded Concepts, LLC430,557+64,467 (+17.61%)0.12%$9 MOct 28, 2026
50Envestnet Asset Management Inc429,089+32,135 (+8.10%)0.12%$9 MNov 16, 2026
51Public Employees Retirement Association Of Colorado426,516+106,700 (+33.36%)0.12%$9 MNov 12, 2026
52Alliancebernstein L.P.419,926-13,300 (-3.07%)0.12%$8 MNov 16, 2026
53Hillsdale Investment Management Inc.418,679-230,500 (-35.51%)0.12%$8 MNov 12, 2026
54Rhumbline Advisers403,210-1,533 (-0.38%)0.12%$8 MNov 10, 2026
55Legal & General Group Plc402,424+6,779 (+1.71%)0.12%$8 MNov 16, 2026
56RPg Family Wealth Advisory, LLC401,494-352,686 (-46.76%)0.12%$8 MNov 12, 2026
57Victory Capital Management Inc399,353-122,535 (-23.48%)0.11%$8 MNov 10, 2026
58Franklin Templeton Inc352,793-45,396 (-11.40%)0.10%$7 MNov 12, 2026
59Informed Momentum Co LLC341,465+3,802 (+1.13%)0.10%$7 MNov 16, 2026
60Credit Agricole S A328,300+114,013 (+53.21%)0.09%$7 MNov 13, 2026
61Swiss National Bank306,700-13,300 (-4.16%)0.09%$6 MNov 12, 2026
62Millennium Management LLC294,727+279,966 (+1896.66%)0.08%$6 MNov 16, 2026
63UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC286,022+51,249 (+21.83%)0.08%$6 MNov 16, 2026
64Osaic Holdings, Inc.275,228+140,608 (+104.45%)0.08%$6 MNov 12, 2026
65HRT Financial LP273,633New0.08%$6 MNov 13, 2026
66Danske Bank A/s271,291New0.08%$5 MNov 9, 2026
67Healthcare Of Ontario Pension Plan Trust Fund246,781-26,056 (-9.55%)0.07%$5 MNov 13, 2026
68Mariner, LLC245,906-67,819 (-21.62%)0.07%$5 MNov 12, 2026
69Russell Investments Group, Ltd.232,670-117,759 (-33.60%)0.07%$5 MNov 6, 2026
70Signature Wealth Management Partners, LLC232,426New0.07%$5 MOct 21, 2026
71ExodusPoint Capital Management, LP232,171-24,672 (-9.61%)0.07%$5 MNov 16, 2026
72Price T Rowe Associates Inc /MD/227,433-3,564 (-1.54%)0.07%$5 MNov 16, 2026
73Stifel Financial Corp224,857+11,260 (+5.27%)0.06%$5 MNov 12, 2026
74Segall Bryant & Hamill, LLC223,019-17,041 (-7.10%)0.06%$4 MNov 16, 2026
75Martingale Asset Management L P222,931-60,102 (-21.23%)0.06%$4 MNov 12, 2026
76Odyssean, LLC213,239+29,732 (+16.20%)0.06%$4 MNov 16, 2026
77NFJ Investment Group, LLC201,685-16,609 (-7.61%)0.06%$4 MNov 9, 2026
78Quantinno Capital Management LP201,561-7,469 (-3.57%)0.06%$4 MNov 13, 2026
79Paralel Advisors LLC187,941+2,110 (+1.14%)0.05%$4 MNov 10, 2026
80Natixis Advisors, LLC187,734+60,068 (+47.05%)0.05%$4 MNov 13, 2026
81Wilshire Advisors LLC187,361New0.05%$4 MNov 12, 2026
82Artemis Investment Management LLP186,1250 (0.00%)0.05%$4 MOct 8, 2026
83Citigroup Inc183,161-31,882 (-14.83%)0.05%$4 MNov 4, 2026
84California State Teachers Retirement System179,821-22,841 (-11.27%)0.05%$4 MNov 13, 2026
85Two Sigma Investments, LP175,170-58,100 (-24.91%)0.05%$4 MNov 16, 2026
86Zacks Investment Management172,369New0.05%$3 MNov 16, 2026
87Virtus Wealth Solutions LLC159,140New0.05%$3 MNov 3, 2026
88State Of Wisconsin Investment Board158,908+36,922 (+30.27%)0.05%$3 MNov 16, 2026
89VANGUARD ASSET MANAGEMENT, Ltd156,754+41,570 (+36.09%)0.04%$3 MNov 13, 2026
90State Board Of Administration Of Florida Retirement System155,270-51,526 (-24.92%)0.04%$3 MNov 13, 2026
91Nomura Asset Management Co LTD152,602+98,624 (+182.71%)0.04%$3 MNov 12, 2026
92Globeflex Capital L P152,428+5,920 (+4.04%)0.04%$3 MNov 16, 2026
93Deutsche Bank AG\148,506-22,982 (-13.40%)0.04%$3 MNov 6, 2026
94Jones Financial Companies Lllp148,022+37,543 (+33.98%)0.04%$3 MNov 13, 2026
95Corient Private Wealth LP146,470-4,228 (-2.81%)0.04%$3 MNov 16, 2026
96CANADA LIFE ASSURANCE Co143,704+2,926 (+2.08%)0.04%$3 MNov 13, 2026
97O'shaughnessy Asset Management, LLC141,490-3,215 (-2.22%)0.04%$3 MNov 12, 2026
98Barclays PLC131,485+21,122 (+19.14%)0.04%$3 MNov 6, 2026
99Y-Intercept (Hong Kong) Ltd130,358+42,215 (+47.89%)0.04%$3 MOct 16, 2026
100Empowered Funds, LLC117,478New0.03%$2 MNov 13, 2026

All 334 institutional investors, with who bought and sold →

Mutual funds holding Amneal Pharmaceuticals, Inc.#

246 funds in 2 countries hold shares worth $1.2 B (about 21.0% of the company). Since their previous reports 125 added shares and 75 sold, buying $67 M net. By country: USA 245 ($1.2 B), Sweden 1 ($1 M).
Mutual funds holding Amneal Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 iShares Core S&P Small-Cap ETFBlackRock Fund Advisors10.38 M$180 M3.0%0.16%+1.9%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.5.56 M$96 M1.6%<0.01%+0.9%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors4.38 M$76 M1.3%0.09%+19%Jun 30, 2026
🇺🇸 Vanguard Small-Cap Index FundThe Vanguard Group, Inc.4.03 M$70 M1.2%0.04%+1.2%Jun 30, 2026
🇺🇸 Vanguard Small-Cap Value Index FundThe Vanguard Group, Inc.2.55 M$44 M0.73%0.07%+0.4%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.97 M$34 M0.57%0.03%+4.2%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.86 M$34 M0.53%0.10%+26%Jul 31, 2026
🇺🇸 Invesco S&P SmallCap Momentum ETFInvesco Capital Management LLC1.84 M$34 M0.53%1.1%+25%Jul 31, 2026
🇺🇸 State Street SPDR Portfolio S&P 600 Small Cap ETFSSGA Funds Management, Inc.1.59 M$27 M0.45%0.16%+3.3%Jun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP1.24 M$23 M0.35%0.11%+0.4%Jul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC1.20 M$21 M0.34%0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors1.19 M$21 M0.34%0.14%+545%Jun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP1.07 M$20 M0.31%0.13%+3.9%Jul 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP1.00 M$18 M0.29%0.23%+0.1%Jul 31, 2026
🇺🇸 Invesco Pharmaceuticals ETFInvesco Capital Management LLC965,545$18 M0.28%3.7%+45%Jul 31, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.880,942$16 M0.25%0.07%no changeJul 31, 2026
🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC880,150$16 M0.25%0.40%−1.9%Jul 31, 2026
🇺🇸 iShares S&P Small-Cap 600 Growth ETFBlackRock Fund Advisors927,710$16 M0.27%0.20%+5.6%Jun 30, 2026
🇺🇸 Columbia Small Cap Value and Inflection FundColumbia Management Investment Advisers, LLC979,518$13 M0.28%1.5%+3.9%May 31, 2026
🇺🇸 Vanguard Tax-Managed Small-Cap FundThe Vanguard Group, Inc.722,603$13 M0.21%0.11%no changeJun 30, 2026
🇺🇸 Neuberger Intrinsic Value FundNeuberger Berman Investment Advisers LLC940,108$12 M0.27%0.82%−0.1%May 31, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC684,817$12 M0.20%0.20%+4.8%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC875,635$12 M0.25%0.03%−2.5%May 31, 2026
🇺🇸 Applied Finance Explorer FundApplied Finance Advisors, LLC606,953$11 M0.17%1.1%no changeJul 31, 2026
🇺🇸 Nuveen Quant Small/Mid Cap Equity FundTeachers Advisors, LLC590,790$11 M0.17%0.40%no changeJul 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.819,083$11 M0.24%0.05%−0.5%May 31, 2026
🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc.607,932$11 M0.17%0.09%+207%Jun 30, 2026
🇺🇸 State Street SPDR S & P 600 Small Cap Growth ETFSSGA Funds Management, Inc.596,295$10 M0.17%0.20%+11%Jun 30, 2026
🇺🇸 iShares S&P Small-Cap 600 Value ETFBlackRock Fund Advisors593,327$10 M0.17%0.13%−10%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.772,909$10 M0.22%0.06%+3.7%May 31, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.498,837$9 M0.14%0.28%+12%Jun 30, 2026
🇺🇸 VictoryShares US Small Mid Cap Value Momentum ETFVictory Capital Management Inc.496,929$9 M0.14%0.49%+14%Jun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP453,710$8 M0.13%0.02%no changeJul 31, 2026
🇺🇸 iShares U.S. Pharmaceuticals ETFBlackRock Fund Advisors448,079$8 M0.13%0.68%−5.6%Jun 30, 2026
🇺🇸 Vanguard S&P Small-Cap 600 Index FundThe Vanguard Group, Inc.587,289$8 M0.17%0.13%+0.8%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.414,058$8 M0.12%0.10%+25%Jul 31, 2026
🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc.426,750$7 M0.12%1.7%−8.1%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors396,443$7 M0.11%0.04%−63%Jun 30, 2026
🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors353,284$6 M0.10%0.16%+9.5%Jul 31, 2026
🇺🇸 State Street SPDR S & P 600 Small Cap Value ETFSSGA Funds Management, Inc.365,082$6 M0.10%0.13%+3.2%Jun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.475,933$6 M0.14%0.03%+1.1%May 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP327,358$6 M0.09%0.02%no changeJul 31, 2026
🇺🇸 Allspring Opportunity FundAllspring Funds Management, LLC337,273$6 M0.10%0.31%−1.8%Jun 30, 2026
🇺🇸 Congress SMid Growth ETFCongress Asset Management Company310,580$6 M0.09%1.3%newJul 31, 2026
🇺🇸 First Trust Mid Cap Core AlphaDEX FundFirst Trust Advisors L.P.297,521$5 M0.09%0.40%+1.6%Jul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC312,418$5 M0.09%0.09%+26%Jun 30, 2026
🇺🇸 First Trust Mid Cap Growth AlphaDEX FundFirst Trust Advisors L.P.265,125$5 M0.08%0.84%+20%Jul 31, 2026
🇺🇸 JNL Small Cap Index FundJackson National Asset Management, LLC269,365$5 M0.08%0.16%+2.6%Jun 30, 2026
🇺🇸 Schwab Fundamental U.S. Small Company ETFCharles Schwab Investment Management, Inc.329,065$4 M0.09%0.05%−18%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors246,891$4 M0.07%<0.01%+2.5%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.232,604$4 M0.07%0.42%+13%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC315,959$4 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC226,583$4 M0.07%0.10%+27%Jul 31, 2026
🇺🇸 Convergence Long/Short Equity ETFConvergence Investment Partners, LLC.305,100$4 M0.09%0.65%+115%May 31, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP209,911$4 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 Virtus NFJ Small-Cap Value FundVirtus Investment Advisers, LLC201,102$3 M0.06%1.3%newJun 30, 2026
🇺🇸 Invesco S&P SmallCap 600 Revenue ETFInvesco Capital Management LLC264,304$3 M0.08%0.19%newMay 31, 2026
🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P.199,963$3 M0.06%0.40%−2.9%Jun 30, 2026
🇺🇸 SRH U.S. Quality GARP ETFParalel Advisors LLC187,941$3 M0.05%1.6%+1.1%Jul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC257,697$3 M0.07%<0.01%+3.5%May 31, 2026
🇺🇸 Allspring Common Stock FundAllspring Funds Management, LLC195,798$3 M0.06%0.50%+39%Jun 30, 2026
🇺🇸 Column Small Cap Select FundTrust for Professional Managers256,310$3 M0.07%0.18%+0.3%May 31, 2026
🇺🇸 Columbia Small Cap Index FundColumbia Management Investment Advisers, LLC253,406$3 M0.07%0.13%−6.2%May 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC180,824$3 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P.180,457$3 M0.05%0.25%+25%Jul 31, 2026
🇺🇸 Carillon Chartwell Small Cap FundCarillon Tower Advisers, Inc.186,484$3 M0.05%1.3%no changeJun 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.185,243$3 M0.05%0.19%no changeJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC185,187$3 M0.05%0.08%+18%Jun 30, 2026
🇺🇸 Putnam Small Cap Value FundPutnam Investment Management, LLC239,600$3 M0.07%1.1%+4.9%May 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC167,953$3 M0.05%0.11%−14%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC177,638$3 M0.05%0.14%+683%Jun 30, 2026
🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC226,564$3 M0.07%0.71%−24%May 31, 2026
🇺🇸 Tax-Managed U.S. Mid & Small Cap FundRussell Investment Management, LLC161,781$3 M0.05%0.14%no changeJul 31, 2026
🇺🇸 Schwab Small-Cap Equity FundCharles Schwab Investment Management, Inc.160,931$3 M0.05%0.45%−41%Jul 31, 2026
🇺🇸 Allspring SMID Core ETFAllspring Funds Management, LLC165,979$3 M0.05%2.4%—Jun 30, 2026
🇺🇸 Principal U.S. Small-Cap ETFPrincipal Global Investors, LLC155,101$3 M0.04%0.12%+7.6%Jun 30, 2026
🇺🇸 U.S. Small Cap Growth PortfolioDimensional Fund Advisors LP145,122$3 M0.04%0.13%−5.9%Jul 31, 2026
🇺🇸 Invesco Dorsey Wright Healthcare Momentum ETFInvesco Capital Management LLC143,351$3 M0.04%1.1%newJul 31, 2026
🇺🇸 PSF Small-Cap Stock Index PortfolioPGIM INVESTMENTS LLC146,750$3 M0.04%0.16%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC188,463$2 M0.05%<0.01%+4.0%May 31, 2026
🇺🇸 SmallCap S&P 600 Index FundPrincipal Global Investors, LLC126,926$2 M0.04%0.17%−4.9%Jul 31, 2026
🇺🇸 Carillon Chartwell Small Cap Growth FundCarillon Tower Advisers, Inc.133,744$2 M0.04%1.2%+9.6%Jun 30, 2026
🇺🇸 PGIM Jennison Blend FundPGIM INVESTMENTS LLC166,555$2 M0.05%0.19%+81%May 29, 2026
🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc.124,301$2 M0.04%0.19%−6.7%Jun 30, 2026
🇺🇸 SEI Select Small Cap ETFSEI INVESTMENTS MANAGEMENT CORPORATION120,630$2 M0.03%0.36%+9.1%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation120,602$2 M0.03%0.09%+19%Jun 30, 2026
🇺🇸 Empower S&P Small Cap 600 Index FundEmpower Capital Management, LLC120,458$2 M0.03%0.16%no changeJun 30, 2026
🇺🇸 SIMT Small Cap Growth FundSEI Institutional Managed Trust116,343$2 M0.03%0.64%−7.1%Jun 30, 2026
🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust115,552$2 M0.03%0.39%−3.2%Jun 30, 2026
🇺🇸 Vanguard S&P Small-Cap 600 Value Index FundThe Vanguard Group, Inc.149,030$2 M0.04%0.10%−0.2%May 31, 2026
🇺🇸 Thrivent Small Cap Index PortfolioThrivent Financial for Lutherans113,125$2 M0.03%0.16%−0.2%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.105,437$2 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Small-Cap Value FundBridgeway Capital Management, LLC106,449$2 M0.03%0.54%no changeJun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.135,550$2 M0.04%0.18%−1.5%May 31, 2026
🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc.100,542$2 M0.03%0.25%no changeJun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC100,235$2 M0.03%0.26%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC94,028$2 M0.03%<0.01%+5.6%Jul 31, 2026
🇺🇸 Small Company FundAmerican Century Investment Management, Inc.95,773$2 M0.03%0.85%+33%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.93,914$2 M0.03%<0.01%−5.8%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.123,308$2 M0.04%0.10%+2.5%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Amneal Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$7.7 M
5 sales, 4 insiders
Net, 12 months
-$7.7 M
open market only
Insiders on file
34
since
-$46.0 M$0May 2024: bought $0 (0 trades), sold $256 K (2 trades)May 24Aug 2024: bought $0 (0 trades), sold $1.3 M (3 trades)Nov 2024: bought $0 (0 trades), sold $968 K (5 trades)NovJan 2025: bought $0 (0 trades), sold $641 K (2 trades)Feb 2025: bought $0 (0 trades), sold $651 K (1 trades)FebMar 2025: bought $0 (0 trades), sold $46.0 M (7 trades)Apr 2025: bought $0 (0 trades), sold $664 K (1 trades)AprMay 2025: bought $0 (0 trades), sold $821 K (4 trades)Jun 2025: bought $0 (0 trades), sold $1.2 M (2 trades)JunAug 2025: bought $0 (0 trades), sold $10.4 M (11 trades)Nov 2025: bought $0 (0 trades), sold $2.2 M (2 trades)NovMay 2026: bought $0 (0 trades), sold $451 K (1 trades)Aug 2026: bought $0 (0 trades), sold $7.2 M (4 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Amneal Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed J. Kevin BuchiDirectorGift-20,445——75,077Form 4
filed J. Kevin BuchiDirectorOption exercise+20,445$14.45$295 K95,522Form 4
filed Andrew S. BoyerExecutive Vice PresidentGift-80,000——193,646Form 4
filed Andrew S. BoyerExecutive Vice PresidentGift-152,426——273,646Form 4
filed John KielyDirectorSell-50,000$17.64$882 K210,252Form 4
filed John KielyDirectorGift-10,000——200,252Form 4
filed Nikita ShahExecutive Vice PresidentSell-146,403$17.51$2.6 M253,390Form 4
filed Jason B. DalyEVP, Chief Legal OfficerSell-210,000$17.40$3.7 M35,171Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Ownership and subsidiaries

Source: GLEIF
Amneal Pharmaceuticals, Inc. directly owns 1 registered entity:

Markets and events: Amneal Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
11.4 M
2.79 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 14,634 shares at $19.25
  • : 160 shares at $18.08
  • : 90,162 shares at $17.44
  • : 294 shares at $17.99
  • : 191 shares at $17.66

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Amneal Pharmaceuticals, Inc. scorecard#

Passes 14 of the 21 checks that could be worked out: strongest in growth (6 of 6), weakest in valuation (1 of 6). Fiscal year 2025; market cap of Oct 16, 2026.

  • Valuation1 of 6
    • ✗P/E below its peers' median50.3×P/E 50.3× against Pharmaceutical's median of 39.4×.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median2.1×Price to sales 2.1× against Pharmaceutical's median of 3.5×.
    • ✗Free cash flow yield above 5%4.0%Free cash flow is 4.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yield2.0%Earnings yield 2.0% against the 10-year Treasury's 5.15% on 2026-11-13.
    • ✗The price assumes slower growth than the last three years'14.9%The price assumes 14.9% a year for ten years; revenue grew 10.9% a year over the last three.
  • Growth6 of 6
    • ✓Revenue grew in the newest year8.1%Revenue up 8.1% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years10.9%10.9% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median10.9%10.9% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✓Earnings per share grew in the newest year0.22 vs -0.38Diluted EPS 0.22 in fiscal 2025 against -0.38 the year before (report's currency).
    • ✓Net income higher than five years earlier$72 M$72 M in fiscal 2025 against $68 M in 2020.
    • ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
  • Profitability4 of 5
    • ✓Profitable in the newest year$72 MNet income $72 M in fiscal 2025.
    • ✗Profitable in each of the last five years2 of 5Profitable in 2 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median13.1%13.1% against Pharmaceutical's median of 1.8% (74 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • ✓Return on invested capital above 10%16.5%16.5% in fiscal 2025.
    • ✓Operating margin wider than three years earlier13.1%13.1% in fiscal 2025 against -4.3% in 2022.
  • Financial health3 of 3
    • ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.17 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone2.38Z-score 2.38 (grey zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year5.1%Diluted shares up 5.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Amneal Pharmaceuticals, Inc.'s statements, beside the median of Pharmaceutical.

Amneal Pharmaceuticals, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin13.1%1.8%
Net margin2.4%-1.5%
Revenue growth, 3 years a year10.9%2.5%
Revenue growth8.1%7.3%
Free cash flow margin8.9%6.0%

7of 9on the Piotroski tests of financial strength

  • The share count rose 5.1% in the year.
  • Shareholders' equity is negative: -$71 million.
  • Revenue has grown 6 years in a row.
  • Free cash flow has been positive 6 years in a row.

Amneal Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Amneal Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue3,0192,7942,3942,2122,0941,9931,6261,6631,0341,018
Cost of revenue1,9051,7741,5731,428r1,325r1,3301,147939r507421
Gross profit1,1131,020821785769628353716526597
Research and development186191164196202180188194171179
Selling, general and administrative527476430400366327290228r109119
Operating income394249204−9515391−249−20245285
Other non-operating income (expense)−255−304−245−153−121−12728−183−74−70
Income before tax139−55−40−24831−36−220−203171215
Income tax11198.56.711−104383−1.42.05.4
Net income including minority interests128−74−49−2552069−604−201169209
Minority interests' share of net income564335−1259.5−22−242−331.72.0
Net income attributable to shareholders72−117−84r−2711368r−604r−2000
Earnings per share, basic0.23-0.38-0.48-0.860.070.62-2.74-0.16——
Earnings per share, diluted0.22-0.38-0.48-0.860.070.61-2.74-0.16——
Shares, weighted average (basic)313309176151149147132127——
Shares, weighted average (diluted)325309176151152149132127——
Balance sheet
Cash and cash equivalents28211192r2624834115121374r27
Receivables———742663639604481351—
Inventory606612581531489491381457284—
Other current assets988183104110737012842—
Current assets1,9111,5881,3781,4121,5201,5521,2101,287772r—
Property, plant and equipment443425448470514478478544487—
Right-of-use (leased) assets54424356605970———
Goodwill5955975995995935234204262628
Other intangible assets5637328901,0961,1671,3051,3831,65545—
Total assets3,6783,5013,4733,7993,9404,0063,6664,3531,342r—
Accounts payable—259144166131r153r103r115r70—
Debt due within a year6.822434303144212189r—
Current liabilities8821,130847753677677550554297r—
Long-term debt2,5652,1622,3862,5922,6802,7352,6092,6311,355r—
Non-current liabilities2,7912,4162,5652,8382,8792,9722,7692,9031,421—
Total liabilities————————0—
Retained earnings−535−607−490−406−276−287−378−21−383—
Shareholders' equity−71−109202983603032325050—
Minority interests−0.5−0.20.2−1146.642115392——
Total equity−71−110201843673453478960—
Total liabilities and equity3,6783,5013,4733,7993,9404,0063,6664,3531,342r—
Shares outstanding————————0.0—
Cash-flow statement
Share-based compensation3228273228212216800
Cash from operating activities340295346652423791.7250234115
Capital expenditure−70−52−43−46−48−56−47−83−95−123
Intangible assets bought−16−15−22−42−1.7−4.4−50−14−20−1.9
Acquisitions, net of cash acquired—00−85−147−2510−32500
Cash from investing activities−112−63−69−174−194−318−20−396−99−125
Debt issued2,695021800—————
Dividends paid—————00−183−375−201
Cash from financing activities−32−212−213−107−138132−46288−95−19
Exchange-rate effect on cash−1.7−1.00.1−5.70.11.0−2.2−0.7−0.21.5
Change in cash1951964−222−90194−6614140−28
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Amneal Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Subtotal dosage forms$1.7 B57%
  • Oral solid$726 M24%
  • Subtotal therapeutic classes$528 M17%
  • Distribution$408 M14%
  • Central nervous system$333 M11%
  • Government$270 M8.9%
  • Other dosage forms$252 M8.4%
  • Auto-injector$233 M7.7%
  • Transdermal$188 M6.2%
  • Injectable$161 M5.3%
  • Hormonal / allergy$155 M5.1%
  • Biosimilar$100 M3.3%
  • Oral liquid$73 M2.4%
  • Other therapeutic classes$40 M1.3%
  • Institutional$35 M1.2%
  • Other$31 M1.0%
  • International$12 M0.4%
  • License agreement$1 M0.0%

Business segments

  • Affordable Medicines$1.7 B58%
  • AvKARE$745 M25%
  • Specialty$529 M18%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Amneal Pharmaceuticals, Inc. operates: 8 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 32 subsidiaries on file.

Present: offices, subsidiaries, branches or revenue (8 countries)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.
Amneal Pharmaceuticals, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters3 offices18 subsidiaries—
🇮🇳 India6 subsidiaries—
🇮🇪 Ireland3 subsidiaries—
🇩🇪 Germany1 subsidiary—
🇲🇽 Mexico1 subsidiary—
🇸🇬 Singapore1 subsidiary—
🇨🇭 Switzerland1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Amneal Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$8.7 M
Chintu Patel, Chirag Patel
Other top executives, average
$3.0 M
the CEO earned 2.9× this
$100 invested is now
$276
peer group: $156
Amneal Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chintu Patel, Chirag Patel$8.7 M$24.4 M$3.0 M$276 (peers $156)
2024Chintu Patel, Chirag Patel$7.2 M$11.9 M$2.6 M$173 (peers $118)
2023Chirag Patel, Chintu Patel$2.4 M$9.5 M$1.7 M$133 (peers $109)
2022Chintu Patel, Chirag Patel$5.1 M−$1.8 M$2.3 M$44 (peers $108)
2021Chintu Patel, Chirag Patel$4.8 M$1.4 M$2.4 M$105 (peers $113)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Amneal Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 5 · New debt 3 · Unregistered share sale 2 · Shareholder vote 4 · Results announced 14

Amneal Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Acquisition or sale completedMaterial agreementNew debtUnregistered share sale8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Material agreementUnregistered share saleResults announced8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K/A
Material agreementNew debt8-K
Directors and officersResults announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K/A
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 3, 2026

Lobbying by Amneal Pharmaceuticals, Inc.#

$1.8 M spent on lobbying the US Congress and federal agencies in 2025, most often on health issues and manufacturing.

Lobbying, 2025
$1.8 M
#247 among companies on value.today
Own lobbyists
Yes
files its own reports
Firms hired
2
in 2025
2026 so far
$590 K
  • Health Issues8 reports
  • Manufacturing4 reports

Lobbying firms hired in 2025

Tarplin, Downs & Young, LLC $240 K · OGR $80 K

The firms' fees are part of Amneal Pharmaceuticals, Inc.'s own reported expenses, so they are not added again.

Amneal Pharmaceuticals, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$590 K$590 K9
2025$1.8 M$1.8 M12
2024$1.5 M$1.5 M8
2023$290 K—4
2022$200 K—5
2021$380 K—8
2020$170 K—3
2019$20 K—1
2018$100 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Amneal Pharmaceuticals”, “Amneal Pharmaceutical” and “AMNEAL PHARMACEUTICALS”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Amneal Pharmaceuticals, Inc.#

37 labor condition applications certified in fiscal 2026 for 37 positions, at a median wage of $113 K a year.

Certified, FY2026
37
#385 among companies on value.today
Worker positions
37
Median wage offered
$113 K
a year, full-time
Applications filed
39
Amneal Pharmaceuticals, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Scientist, Quality ControlChemists4$97 K
Associate Process EngineerIndustrial Engineers2$82 K
Lead Scientist, Quality ControlChemists2$113 K
Sr. Scientist, Analytical R&DChemists2$103 K
AI EngineerComputer Occupations, All Other1$79 K
Associate Director, Manufacturing OperationsIndustrial Production Managers1$173 K
Associate Director, R&D Program MgmtChemists1$189 K
Associate Manager, Quality ControlChemists1$116 K
Associate Validation EngineerIndustrial Engineers1$81 K
Director, Commercial AnalyticsFinancial Quantitative Analysts1$220 K

Where: Piscataway, NJ 29 · Branchburg, NJ 5 · Bridgewater, NJ 3

Amneal Pharmaceuticals, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY20263737$113 K39
FY20252525$105 K25
FY20243232$104 K34
FY20233333$105 K33
FY20223132$96 K33
FY20214141$95 K42
FY20203234$92 K34

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as AMNEAL PHARMACEUTICALS LLC

FDA drug approvals: Amneal Pharmaceuticals, Inc.#

519 approved applications held, 2 of them new molecular entities; 12 approvals and 0 new uses in 2026.

Approvals held
519
New molecular entities
2
New uses approved
5
efficacy supplements
Generics
504
12 new drugs, 3 biologics
Amneal Pharmaceuticals, Inc.: latest FDA approvals
ApprovedDrugKind
2026-11-02CyclophosphamideCyclophosphamide · ANDA210890Generic drug (ANDA)
2026-10-15Sodium PhosphatesSodium Phosphate, Dibasic, Heptahydrate, Sodium Phosphate, Monobasic, Monohydrate · ANDA218274Generic drug (ANDA)
2026-09-18Lanreotide AcetateLanreotide Acetate · ANDA218217Generic drug (ANDA)
2026-07-09Sodium BicarbonateSodium Bicarbonate · NDA220790New drug (NDA)
2026-06-08MacitentanMacitentan · ANDA211000Generic drug (ANDA)
2026-06-02RomidepsinRomidepsin · ANDA219099Generic drug (ANDA)
2026-06-01PhytonadionePhytonadione · ANDA217734Generic drug (ANDA)
2026-05-14TretinoinTretinoin · ANDA217497Generic drug (ANDA)
2026-01-28Sertraline HydrochlorideSertraline Hydrochloride · ANDA219655Generic drug (ANDA)
2026-01-26Cupric ChlorideCupric Chloride · ANDA217287Generic drug (ANDA)
2026-01-14Eltrombopag OlamineEltrombopag Olamine · ANDA212884Generic drug (ANDA)
2026-01-13Sodium BicarbonateSodium Bicarbonate · ANDA217523Generic drug (ANDA)
2025-12-31Ketamine HydrochlorideKetamine Hydrochloride · ANDA220380Generic drug (ANDA)
2025-12-19BoncresaDenosumab-Mobz · BLA761456Biologic (BLA)
2025-12-19OziltusDenosumab-Mobz · BLA761457Biologic (BLA)
2025-12-12DeflazacortDeflazacort · ANDA217173Generic drug (ANDA)
2025-12-08EpinephrineEpinephrine · ANDA218208Generic drug (ANDA)
2025-11-28CyclosporineCyclosporine · ANDA211909Generic drug (ANDA)
2025-11-13IohexolIohexol · ANDA217737Generic drug (ANDA)
2025-11-04PhytonadionePhytonadione · ANDA216601Generic drug (ANDA)
2025-10-29Neomycin And Polymyxin B Sulfates And HydrocortisoneHydrocortisone, Neomycin Sulfate, Polymyxin B Sulfate · ANDA217803Generic drug (ANDA)
2025-10-14EpinephrineEpinephrine · ANDA217485Generic drug (ANDA)
2025-10-02Labetalol HydrochlorideLabetalol Hydrochloride · ANDA218870Generic drug (ANDA)
2025-09-30Neomycin And Polymyxin B Sulfates And HydrocortisoneHydrocortisone, Neomycin Sulfate, Polymyxin B Sulfate · ANDA217735Generic drug (ANDA)
2025-09-26Calcitonin-SalmonCalcitonin Salmon · ANDA216294Generic drug (ANDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (AMNEAL, AMNEAL PHARMS and IMPAX LABS), so they follow acquisitions

Product recalls by Amneal Pharmaceuticals, Inc.#

16 recalls since 2015, 248,710 units in the notices that give a number. Drugs (FDA): 16.

Amneal Pharmaceuticals, Inc.: product recalls
DateWhat and whyUnitsNotice
Estradiol Gel, 0.1%, 0.25 mg, 30-packets per carton, Rx only, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08907, NDC 69238-2452-3.Defective Container; packets were found to be either empty or partially full.DrugsClass II2,592D-0873-2026
Primidone Tablets, USP, 50 mg, 100 Tablets per Bottle, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad 382213, INDIA. Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC: 53746-544-01Cross Contamination with Other Products: due to a potential for cross-contamination with Acemetacin API due to an issue at the API manufacturer.DrugsClass III27,936D-0585-2026
traMADol Hydrochloride Tablets, USP, 50 mg, 500-count bottles, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad 382220, India, Distributed by: Amneal Pharmaceuticals LLC, Glasgow, KY 42141, NDC 60219-2348-5.Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).DrugsClass II29,542D-0408-2026
Magnesium Sulfate in Water for Injection, 4g/100 mL (40mg/mL) IV bag, further packaged in cartons of 12 x 100 mL IV bags, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad, 382110, India, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC 70121-1720-3.Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.DrugsClass I784D-0478-2026
chlorproMAZINE Hydrochloride Tablets, USP, 200 mg, 100-count bottles Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad 382213, INDIA; Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC 69238-1062-1. (and 4 more products)Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism was detected on any tablets.DrugsClass II3,363D-0619-2025
Sulfamethoxazole and Trimethoprim Tablets, USP, 400 mg/80 mg, Rx Only, a) 100 Tablets per Bottle, NDC: 65162-271-10, b) 500 Tablets per Bottle, NDC: 65162-271-50, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Oral Solid Dosage Unit, Ahmedabad, 382213, INDIA, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807.Microbial contamination of non-sterile products: tablets may exhibit black spots due to microbial contamination.DrugsClass I6,396D-0488-2025
Ropivacaine Hydrochloride Injection, USP, 0.5%, 500 mg per 100 mL (5mg/mL), Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Mehsana, India, , Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807 NDC 70121-1734-1 (bag); NDC 70121-1734-3 (box)Presence of Particulate MatterDrugsClass I62D-0402-2025
Methotrexate Tablets, USP, 2.5mg, 100-count Bottle, RX Only, Distributed By: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC# 69238-1423-1Presence of Foreign Tablets: Potential presence of Fludrocortisone Acetate Tablet USP 0.1 mg within the Methotrexate 2.5 mg 100-count Bottle.DrugsClass III12,624D-0629-2024
Ranitidine Tablets, USP 300 mg - a).30-count bottles (NDC 65162-254-30), b).100-count bottles (NDC 65162-254-10) and c). 250-count bottles (NDC 65162-254-25). (and 4 more products)CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in APIDrugsClass II—D-0613-2020
Isotretinoin Capsules, USP 10 mg. Rx Only, 3 Prescription Blister Packs of 10- Capsules Each (30 Capsules)-. Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC 69238-1174-3Failed Impurities/Degradation Specifications: Tretinoin levels slightly above specification limits.DrugsClass III2,460D-0321-2020
Benazepril HCl Tablets, USP 40 mg, 100 count bottles, Rx only, Distributed by Amneal Pharmaceuticals, Bridgewater, NJ NDC 65162-754-10Presence of Foreign Tablet/Capsule; Promethazine HCl tablet found in the Benazepril HCl bottleDrugsClass III9,720D-0134-2020
Methylergonovine Maleate USP 0.2 mg Tablets a) 12 count (NDC 69238-1605-02) and b) 28 count bottles (NDC 69238-1605-08)Presence of Foreign Tablet/Capsule; one Promethazine tablet was found in a bottle of Methylergonovine Maleate tabletsDrugsClass III2,256D-1516-2019
Fosphenytoin Sodium Injection, USP 500 mg PE*/10 mL, Made in India. Distributed by: Amneal Biosciences, Bridgewater, NJ 08807, NDC 70121-1390-1Presence of particulate matterDrugsClass II12,584D-0610-2018
Esterified Estrogens & Methyltestosterone Tablets, USP 1.25 mg/2.5 mg, 100-count bottles, Rx Only, Manufactured by: Ammeal Pharmaceuticals of NY Hauppauge, NY 11788 Distributed by: Seton Pharmaceuticals Manasquan, NJ 08736, NDC 13925-172-01 (and 1 more products)Subpotent Drug: Out of specification assay result in Esterified Estrogen and Methyltestosterone tablets.DrugsClass III19,176D-1439-2019
Fosphenytoin Sodium Injection, USP, 500 mg PE/10 mL (50 mg PE/mL. 10 mL Single Dose Vial, Rx Only. Distributed by: Amneal Biosciences, Bridgewater, NJ 08807. NDC: 70121-1390-7Presence of Particulate MatterDrugsClass II14,000D-0076-2018
Rabeprazole Sodium Delayed Release Tablets, 20 mg, a) 30-count bottle (NDC 65162-0724-03), b) 90-count bottle (NDC 65162-0724-09), Rx Only, Manufactured by Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad INDIA 382220, Distributed by Amneal Pharmaceuticals, Bridgewater, NJ 08807Failed Dissolution SpecificationsDrugsClass II105,215D-0693-2017

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

Layoffs at Amneal Pharmaceuticals, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
550
2018–2019
Latest
—
2019-07-10
Amneal Pharmaceuticals, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2019············—
2018····550·······550
Amneal Pharmaceuticals, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
550 peopleRestructuring planSEC 8-K“The Company currently expects the facility closures to reduce its workforce by approximately 550 positions.”Filing

Source: State WARN notices and SEC 8-K item 2.05

Discuss Amneal Pharmaceuticals, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 3 November 2026automatic update · Nov 3, 2026

    Amneal Pharmaceuticals, Inc. announced results on 3 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $863 million (up 10% from a year earlier) and a net loss of $22 million.

  • Mutual funds: 246 funds hold $1.2 billionautomatic update · Jul 31, 2026

    246 mutual funds in 2 countries hold shares of Amneal Pharmaceuticals, Inc. worth $1.2 billion, about 21.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 125 funds added shares and 75 sold; on balance they bought $67 million. Share splits are not counted as trading.

How Amneal Pharmaceuticals, Inc. compares in Pharmaceutical

  • Market cap$6.7 B · higher than 86% of 393
  • Revenue$3.0 B · higher than 82% of 324
  • Net margin4.2% · higher than 38% of 313
  • Revenue growth8.1% · higher than 53% of 107
  • P/E ratio50.3× · lower than 20% of 172
  • Price / sales2.1× · lower than 56% of 219
  • FCF yield4.0% · higher than 56% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Amneal Pharmaceuticals, Inc.🇺🇸$6.7 B50.3×4.2%+8.1%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 16, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Amneal Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Amneal Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Amneal Pharmaceuticals, Inc.? Suggest a correction